Management of patients with acute coronary syndromes in the United States by platelet Glycoprotein IIb/IIIa inhibition: Insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

Circulation

Volumn 102, Issue 10, 2000, Pages 1093-1100

  Lincoff, A Michael ^a   Harrington, Robert A ^b   Califf, Robert M ^b   Hochman, Judith S ^c   Guerci, Alan D ^d   Ohman, E Magnus ^b   Pepine, Carl J ^e   Kopecky, Steven L ^f   Kleiman, Neal S ⁱ   Pacchiana, Cynthia M ^b   Berdan, Lisa G ^b   Kitt, Michael M ^g   Simoons, Maarten L ^h   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d ST FRANCIS HOSPITAL   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f MAYO CLINIC   (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

^h CARDIALYSIS   (Netherlands)

ⁱ NONE

Author keywords

Angina; Angioplasty; Glycoproteins; Myocardial infarction; Platelets

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034609580     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.10.1093     Document Type: Article

References (13)

1. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
3. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
4. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
5. Thrombolysis in myocardial infarction (TIMI) trial I, phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
6. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries
7. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
8. Comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
9. Differences in the treatment of myocardial infarction between the United States and Canada: A survey of physicians in the GUSTO trial
10. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction
11. Geographic variation in the treatment of acute myocardial infarction
12. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study
13. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy